Anthracyclines: Molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity

Pharmacological Reviews

Volumn 56, Issue 2, 2004, Pages 185-229

  Minotti, Giorgio ^a   Menna, Pierantonio ^a   Salvatorelli, Emanuela ^a   Cairo, Gaetano ^b   Gianni, Luca ^c  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 PROPANEDIAMINE N,N' DIACETAMIDE N,N' DIACETIC ACID; 3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 7 METHYLTHIOMETHYLPACLITAXEL; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BMS 184476; BORTEZOMIB; CPI 0004NA; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; EPIRUBICIN; EVACET; FREE RADICAL; IDARUBICIN; IRON; IRON CHELATE; L 377202; MITOXANTRONE; MX 2; N BENZYLDOXORUBICIN; N BENZYLDOXORUBICIN 14 VALERATE; N TRIFLUOROACETYLDOXORUBICIN; NAVELBINE; NEMORUBICIN; PACLITAXEL; PACLITAXEL DERIVATIVE; PIRARUBICIN; PK 2; PNU 159548; PROTEASOME INHIBITOR; RAZOXANE; SABARUBICIN; TAXANE DERIVATIVE; TELOMERASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALRUBICIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CROSS LINKING; DNA ADDUCT; DNA DAMAGE; DRUG ACCUMULATION; DRUG DESIGN; DRUG DNA BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG RETENTION; DRUG USE; HEART PROTECTION; HUMAN; HYDROGEN BOND; LONG TERM CARE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HEART DISEASES; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2642566088     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: 10.1124/pr.56.2.6     Document Type: Review

References (375)

1. Adams J (2003) The proteasome: structure, function and role in the cell. Cancer Treat Rev 29 (Suppl 1):3-9.
2. Akao M, O'Rourke B, Teshima Y, Seharaseyon J, and Marban E (2003) Mechanistically distinct steps in the mitochondrial death pathway triggered by oxidative stress in cardiac myocytes. Circ Res 92:186-194.
3. Anderlini P, Benjamin RS, Wong FC, Kantarjian HM, Andreeff M, Kornblau SM, O'Brien S, Mackay B, Ewer MS, and Pierce SA (1995) Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 13:2827-2834.
4. Andrieu-Abadie, Jaffrezou JP, Hatem S, Laurent M, Levade T, and Mercadier JJ (1999) L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. FASEB J 13:1501-1510.
5. Animati F, Berettoni M, Cipollone A, Franciotti M, Lombardi P, Monteagudo E, and Arcamone F (1996) New anthracycline disaccharides synthesis of L-daunosaminyl-α(1→4)-2-deoxy-L-rhamnosyl and of L-daunosaminyl-α-(1→4)-2-deoxy- L fucosyl daunorubicin analogues. J Chem Soc Perkin Trans I:1327-1329.
6. Arai M, Tomaru K, Takizawa T, Sekiguchi K, Yokoyama T, Suzuki T, and Nagai R (1998) Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J Mol Cell Cardiol 30:243-254.
7. Arcamone F, Animati F, Berettoni M, Bigioni M, Capranico G, Casazza AM, Caserini C, Cipollone A, De Cesare M, Franciotti M, et al. (1997) Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. J Natl Cancer Inst 89:1217-1223.
8. Arcamone F, Animati F, Bigioni F, Capranico G, Camerini C, Cipolline A, De Cesare M, Ettorre A, Guano F, Mancini S, et al. (1999) Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides. Biochem Pharmacol 57:1133-1139.
9. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, and Voipio-Pulkki L-M (2000) Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 60:1789-1792.
10. Artandi SE, Alson S, Tietze MK, Sharpless NE, Ye S, Greenberg RA, Castrillon DH, Horner JW, Weiler SR, Carrasco RD, and DePinho RA (2002) Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci USA 99:8191-8196.
11. Auner HW, Tinchon C, Linkesch W, Halwachs-Baumann G, and Sill H (2001) Correspondence re: O. J. Arola et al., acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis, Cancer Res (2000) 60:1789-1792. Cancer Res 61:2335-2336.
12. Ax W, Soldan M, Koch L, and Maser E (2000) Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 59:293-300.
13. Bakker M, Droz JP, Hanauske AR, Verweij J, van Oosterom AT, Groen HJ, Pacciarini MA, Domenigoni L, van Weissenbruch F, Pianezzola E, and de Vries EG (1998) Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. Br J Cancer 77:139-146.
14. Bakker M, Renes J, Groenhuijzen A, Visser P, Timmer-Bosscha H, Muller M, Groen HJ, Smit EF, and de Vries EG (1997) Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines. Int J Cancer 73:362-366.
15. Barrett CM, Lewis FL, Roaten JB, Sweatman TW, Israel M, Cleveland JL, and Lothstein L (2002) Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis. Mol Cancer Ther 1:469-481.
16. Batist G, Barton J, Chaikin P, Swenson C, and Welles L (2002) Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother 3:1739-1751.
17. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, et al. (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444-1454.
18. Bellarosa D, Ciucci A, Bullo A, Nardelli F, Manzini S, Maggi CA, and Goso C (2001) Apoptotic events in a human ovarian cancer cell line exposed to anthracyclines. anthracycline analogs is also discussed. J Pharmacol Exp Ther 296:276-283.
19. Benjamin T, Piwnica-Worms D, and Ratner L (2000) Multidrug resistance transporters and modulation. Curr Opin Oncol 12:450-458.
20. Berrak SG, Ewer MS, Jaffe N, Pearson P, Ried H, Zietz HA, and Benjamin RS (2001) Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep 8:611-614.
21. Bertheau P, Plassa F, Espie M, Turpin E, de Roquancourt A, Marty M, Lerebours F, Beuzard Y, Janin A, and de The H (2002) Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 360:852-854.
22. Bezombes C, de Thonel A, Apostolou A, Louat T, Jaffrezou JP, Laurent G, and Quillet-Mary A (2002) Overexpression of protein kinase Czeta confers protection against antileukomic drugs by inhibiting the redox-dependent sphingomyelinase activation. Mol Pharmacol 62:1446-1455.
23. Bianchi G, Albanell J, Eiermann W, Vitali G, Borquez D, Vigano L, Molina R, Raab G, Locatelli A, Vanhauwere B, et al. (2003) Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res 9:5944-5951.
24. Biganzoli L, Cufer T, Bruning P, Coleman RE, Duchateau L, Rapoport B, Nooij M, Delhaye F, Miles D, Sulkes A, et al. (2003) Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of cancer multicenter trial. Cancer 97:40-45.
25. Bigioni M, Salvatore C, Bullo A, Bellarosa D, Iafrate E, Animati F, Capranico G, Goso C, Maggi CA, Pratesi G, et al. (2001) A comparative study of cellular and molecular pharmacology of doxorubicin and MEN 10755, a disaccharide analogue. Biochem Pharmacol 62:63-70.
26. Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, Capranico G, and Animati F (2001) Anthracyclines: selected now dovelopments new developments. Curr Med Chem 1:113-130.
27. Binaschi M, Capranico G, Dal Bo L, and Zunino F (1997) Relationship between lethal effects and topoisomerase II mediated double-strand DNA breaks produced by anthracyclines with different sequence specificity. Mol Pharmacol 51:1053-1059.
28. Binaschi M, Farinosi R, Borgnetto ME, and Capranico G (2000) In vivo site specificity and human isoenzyme selectivity of two topoisomerase II-poisoning anthracyclines. Cancer Res 60:3770-3776.
29. Borchmann P, Hubel K, Schnell R, and Engert A (1997) Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 35:80-83.
30. Bos AM, de Vries EG, Dombernovsky P, Aamdal S, Uges DR, Schrijvers D, Wanders J, Roelvink MW, Hanauske AR, Bortini S, et al. (2001) Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. Cancer Chemother Pharmacol 48:361-369.
31. Brazzolotto X, Andriollo M, Guiraud P, Favier A, and Moulis JM (2003) Interactions between doxorubicin and the human iron regulatory system. Biochim Biophys Acta 1593:209-218.
32. 4S] form by hydrogen peroxide in vitro but is not activated for iron-responsive element binding. J Biol Chem 274:21625-21630.
33. Broker LE and Giaccone G (2002) The role of new agents in the treatment of non-small cell lung cancer. Eur J Cancer 38:2347-2361.
34. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, et al. (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in Phase II studies in patients with cancer. J Clin Oncol 16:187-196.
35. Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, et al. (2003) Chemotherapy-induced apoptosis and Bc1-2 levels correlate with breast cancer response to chemotherapy. Cancer J 9:33-41.
36. Burke BE, Gambliel H, Olson RD, Bauer FK, and Cusack BJ (2000) Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat. Br J Pharmacol 131:1-4.
37. 2+-ATPase. Biochem Biophys Res Commun 303:504-507.
38. Burke PJ and Koch TH (2001) Doxorubicin-formaldehyde conjugate, doxoform: induction of apoptosis relative to doxorubicin. Anticancer Res 21:2753-2760.
39. Burke PJ and Koch TH (2004) Design, synthesis and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells. J Med Chem 47:1193-1206,
40. Cairo G and Pietrangelo A (2000) Iron regulatory proteins in pathobiology. Biochem J 352:241-250.
41. Cairo G, Recalcati S, Pietrangelo A, and Minotti G (2002) The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic Biol Med 32:1237-1243.
42. Cairo G, Ronchi R, Recalcati S, Campanella A, and Minotti G (2003) Nitric oxide and peroxynitrite activate the iron regulatory protein-1 of J774A. 1 macrophages by direct disassembly of the Fe-S cluster of cytoplasmic aconitase. Biochemistry 41:7435-7442.
43. Camarda G, Binaschi Maggi CA, and Goso C (2002) Nuclear factorκB induced in human carcinoma cell line A2780 by the new anthracycline men 10755, is devoid of transcriptional activity. Int J Cancer 102:476-482.
44. Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, Fuller AF Jr, Wilson KS, Puchalski TA, Supko JG, and Seiden MV (2003) Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumors. Gynecol Oncol 90:610-618.
45. Cartoni A, Menna P, Salvatorelli E, Braghiroli D, Giampietro R, Animati F, Urbani A, Del Boccio P, and Minotti G (2004) Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids: novel function for ferrylmyoglobin? J Biol Chem 279:5088-5099.
46. Case DC Jr, Ervin TJ, Boyd MA, Bove LG, Sonneborn HL, and Paul SD (1987) Phase II study of aclarubicin in acute myeloblastic leukemia. Am J Clin Oncol 10:523-526.
47. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, and Leeuwenburgh C (2002) Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity and Bcl-2:Bax ratio. Cancer Res 62:4592-4598.
48. Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, Greider CW, and DePinho RA (1999) p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97:527-538.
49. Cirillo R, Sacco G, Venturella S, Brightwell J, Giachetti A, and Manzini S (2000) Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat. J Cardiovasc Pharmacol 35:100-108.
50. Clarke K, Basser RL, Underhill C, Mitchell P, Bartlett J, Cher L, Findlay M, Dalley D, Pell M, Byrne M, et al. (1999) KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma. J Clin Oncol 17:2579-2584.
51. Clementi ME, Giardina B, Di Stasio E, Mordente A, and Misiti F (2003) Doxorubicin-derived metabolites induce release of cytochrome c and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res 23:2445-2450.
52. Cogan PS and Koch TH (2003) Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specific delivery of a doxorubicin-formaldehyde conjugate. J Med Chem 46:5258-5270.
53. Corna G, Santambrogio P, Minotti G, and Cairo G (2004) Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin. J Biol Chem 279:13738-13745.
54. Cortes J, Estey E, O'Brien S, Giles F, Shen Y, Koller C, Beran M, Thomas D, Keating M, and Kantarjian H (2001) High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 92:7-14.
55. Cowell IG, Okorokov AL, Cutts SA, Padget K, Bell M, Milner J, and Austin CA (2000) Human topoisomerase IIa and IIb interact with the C-terminal region of p53. Exp Cell Res 255:86-94.
56. Cusack BJ, Young SP, Driskell J, and Olson RD (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32:53-58.
57. Cusack BJ, Young SP, Gambliel H, and Olson RD (2002) Effect of aging on cardiac contractility in a rat model of chronic daunorubicin cardiotoxicity. Cardiovasc Toxicol 2:99-109.
58. Cusack JC (2003) Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29 (Suppl 1):21-31.
59. Cutts SM, Rephaeli A, Nudelman A, Hmelnitsky I, and Phillips DR (2001) Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res 61:8194-8202.
60. Cutts SM, Swift LP, Rephaeli A, Nudelman A, and Phillips DR (2003) Sequence specificity of adriamycin-DNA adducts in human tumor cells. Mol Cancer Ther 2:661-670.
61. Dabich L, Bull FE, Beltran G, Athens JW, Coltman CA Jr, Weick JK, Van Slyck EJ, and Amare M (1986) Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study. Cancer Treat Rep 70:967-969.
62. Danesi R, Fogli S, Gennari A, Conte P, and Del Tacca M (2002) Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 41:431
63. Danesi R, Paparelli A, Bernardini N, and Del Tacca M (1988) Cytofluorescence localization and disposition of doxorubicin and doxorubicinol in rat cardiac tissue. Eur J Cancer Clin Oncol 24:1123-1131.
64. DeFeo-Jones D, Garsky VM, Wong BK, Feng DM, Bolyar T, Haskell K, Kiefer DM, Leander K, McAvoy E, Lumma P, et al. (2000) A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med 6:1248-1252.
65. de Groot FM, Broxterman HJ, Adams HP, van Vliet A, Tesser GI, Elderkamp YW, Schraa AJ, Kok RJ, Molema G, Pinedo HM, and Scheeren HW (2002) Design, synthesis and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug. Mol Cancer Ther 1:901-911.
66. de Jonge MJ, Verweij J, van der Gaast A, Valota O, Mora O, Planting AS, Mantel MA, Bosch SV, Lechuga MJ, Fiorentini F, et al. (2002) Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours. Eur J Cancer 38:2407-2415.
67. Della Torre P, Podesta A, Imondi AR, Moneta D, Sammartini U, Arrigoni C, Terron A, and Brughera M (2001) PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential. Cancer Chemother Pharmacol 47:355-360.
68. Deltour L, Foglio MH, and Duester G (1999) Metabolic deficiencies in alcohol dehydrogenase Adh1, Adh3 and Adh4 null mutant mice. J Biol Chem 274:16796-16801.
69. Deng X, Xiao L, Lang W, Gao F, Ruvolo P, and May WS Jr (2001) Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem 276:23681-23688.
70. Denmeade SR, Nagy A, Gao J, Lilja H, Schally AV, and Isaacs JT (1998) Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res 58:2537-2540.
71. Dernell WS, Powers BE, Taatjes DJ, Cogan P, Gaudiano G, and Koch TH (2002) Evaluation of the epidoxorubicin-formaldehyde conjugate, epidoxoform, in a mouse mammary carcinoma model. Cancer Investig 20:713-724.
72. Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, and Hortobagyi GN (1995) Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Clin Cancer Res 1:691-697.
73. D'Incalci M, Schuller J, Colombo T, Zucchetti M, and Riva A (1998) Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Semin Oncol 25 (Suppl 13):16-20.
74. DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin E, Capanna T, Ciardella M, Doyle-Lindrud S, Goodwin S, Fontaine M, et al. (2002) Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol 20:1874-1879.
75. Doroshow JH (1995) Role of reactive-oxygen metabolism in the cardiac toxicity of the anthracycline antibiotics, in: Anthracycline Antibiotics: New Analogues, Methods of Delivery and Mechanisms of Action (Priebe W ed) pp. 259-267, American Chemical Society, Washington, DC.
76. Doroshow JH, Juhasz A, Matsumoto L, and van Balgooy J (2001a) Reactive oxygen metabolism induced by Trastuzumab (Herceptin) in human breast cancer cells. Proc Am Assoc Cancer Res 42:772 (A4145).
77. Doroshow JH, Locker GY, and Myers CE (1980) Enzymatic defences of the mouse heart against reactive oxygen metabolites. J Clin Investig 65:128-135.
78. Doroshow JH, Synold TW, Somlo G, Akman SA, and Gajewski E (2001b) Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. Blood 97:2839-2845.
79. Douki T, Martini R, Ravanat JL, Turesky RJ, and Cadet J (1997) Measurement of 2,6-diamino-4-hydroxy-5-formanudopyrimidine 8-oxo-7,8-dihydroguanine in isolated DNA exposed to gamma radiation in aqueous solution. Carcinogenesis 18:2385-2391.
80. Dowd NP, Scully M, Adderley SR, Cunningham AJ, and Fitzgerald DJ (2001) Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Investig 108:585-590.
81. Drummond DC, Meyer O, Hong K, Kirpotin DB, and Papahadjopoulos (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev Rey 51:692-743.
82. Dubois V, Dasnois L, Lebtahi K, Collot F, Heylen N, Havaux N, Fernandez AM, Lobl TJ, Oliyai C, Nieder M, et al. (2002) CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity and tissue distribution confirm tumor cell selectivity. Cancer Res 62:2327-2331.
83. Dunkern TR, Wedemeyer I, Baumgärtner M, Fritz G, and Kaina B (2003) Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signalling. DNA Repair (Amst) 2:49-60.
84. Edenberg HJ (2000) Regulation of the mammalian alcohol dehydrogenase genes. Prog Nucleic Acid Res Mol Biol 64:295-341.
85. Ejendal KF and Hrycyna CA (2002) Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. Curr Protein Pept Sci 3:503-511.
86. Elmore LW, Rehder CW, Di X, McChesney PA, Jackson-Cook CK, Gewirtz DA, and Holt SE (2002) Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem 277:35509-35515.
87. Escobar PF, Markman M, Zanotti K, Webster K, and Belinson J (2003) Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer. J Cancer Res Clin Oncol 129:651-654.
88. Estorch M, Carrio I, Martinez-Duncker D, Berna L, Torres G, Alonso C, and Ojeda B (1993) Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies. J Clin Oncol 11:1264-1268.
89. Fabel K, Dietrich J, Hau P, Wismeth C, Winner B, Przywara S, Steinbrecher A, Ullrich W, and Bogdahn U (2001) Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92:1936-1942.
90. Fassas A, Buffels R, Anagnostopoulos A, Gacos E, Vadikolia C, Haloudis P, and Kaloyannidis P (2002) Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study. Br J Haematol 116:308-315.
91. Feldman AM, Lorell BH, and Reis SE (2000) Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 102:272-274.
92. Figueiredo-Pereira ME, Chen WE, Li J, and Johdo O (1996) The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20S proteasome. J Biol Chem 271:16455-16459. [Erratum in: J Biol Chem 271:23602.]
93. Figueiredo-Pereira ME, Chen WE, Li J, and Johdo O (1996) The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20S proteasome. J Biol Chem 271:16455-16459. [Erratum in: J Biol Chem 271:23602.]
94. Fink D, Aebi S, and Howell SB (1998) The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4:1-6.
95. Fokkema E, Verweij J, van Oosterom AT, Uges DR, Spinelli R, Valota O, de Vries EG, and Groen HJ (2000) A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study. Br J Cancer 82:767-771.
96. Forrest GL, Gonzalez B, Tseng W, Li X, and Mann J (2000) Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 60:5158-5164.
97. Forssen EA and Ross ME (1994) DaunoXome treatment of solid tumors: preclinical and clinical investigations. J Liposome Res 4:481-512.
98. Foucrier J, Bassaglia Y, Grand MC, Rothen B, Perriard JC, and Scherrer K (2001) Prosomes form sarcomerelike banding patterns in skeletal, cardiac, and smooth muscle cells. Exp Cell Res 266:1933-200.
99. Gabizon A, Goren D, Cohen R, and Barenholz Y (1998) Development of liposomal anthracyclines: from basics to clinical applications. J Controlled Release 53:275-279.
100. Gabizon A, Shmeeda H, and Barenholz Y (2003) Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419-436.
101. Gajewski E, Rao G, Nackerdien Z, and Dizdaroglu M (1990) Modification of DNA bases in mammalian chromatin by radiation-generated free radicals. Biochemistry 29:7876-7882.
102. Gambliel HA, Burke BE, Cusack BJ, Walsh GM, Zhang YL, Mushlin PS, and Olson RD (2002) Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression. Biochem Biophys Res Commun 291:433-438.
103. Gardner PR, Ranieri I, Epstein LB, and White CR (1995) Superoxide radical and iron modulate aconitase activity in mammalian cells. J Biol Chem 270:13339-13405.
104. Gariboldi MB, Ravizza R, Riganti L, Meschini S, Calcabrini A, Marra M, Arancia G, Dolfini E, and Monti E (2003) Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines. Int J Oncol 22:1057-1064.
105. Gennari A, Salvadori B, Donati S, Bengala C, Orlandini C, Danesi R, Del Tacca M, Bruzzi P, and Conte PF (1999) Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol 17:3596-3602.
106. Geroni C, Ripamonti M, Arrigoni C, Fiorentini F, Capolongo L, Moneta D, Marchini S, Della Torre P, Albanese C, et al. (2001) Pharmacological and toxicological aspects of 4-demethoxy-3′-deamino-3′ -aziridinyl-4′-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent. Cancer Res 61:1983-1990.
107. Gervasi G, Agrillo MR, Citti L, Danesi R, and Del Tacca M (1986) Superoxide anion production by adriamycinol from cardiac sarcosomes and by mitochondrial NADH dehydrogenase. Anticancer Res 6:1231-1235.
108. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741.
109. Gianni L (2001) Tolerability in patients receiving trastuzumab with or without chemotherapy. Ann Oncol 12 (Suppl 1):63-68.
110. Gianni L, Dombernowsky P, Sledge G, Martin M, Amadori D, Arbuck SG, Ravdin P, Brown M, Messina M, Tuck D, et al. (2001) Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol 12:1067-1073.
111. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, et al. (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699.
112. Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, and Bonadonna G (1997) Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15:1906-1915.
113. Gibbs DD, Pyle L, Allen M, Vaughan M, Webb A, Johnston SR, and Gore ME (2002) A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer. Br J Cancer 86:1379-1384.
114. Gill PS, Espina BM, Muggia F, Cabriales S, Tulpule A, and Esplin JA (1995) PhaseI/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 13:996-1003.
115. Gille L and Nohl H (1997) Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic Biol Med 23:775-782.
116. Gonsette RE (2003) Mitoxantrone in progressive multiple sclerosis: when and how to treat? J Neurol Sci 206:203-208.
117. Gonzalez B, Akman S, Doroshow J, Rivera H, Kaplan WD, and Forrest GL (1995) Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Cancer Res 55:4646-4650.
118. Gonzalez-Paz O, Polizzi D, De Cesare M, Zunino F, Bigioni M, Maggi CA, Manzini S, and Pratesi G (2001) Tissue distribution, antitumour activity and in vivo apoptosis induction by MEN10755 in nude mice. Eur J Cancer 37:431-437.
119. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, and Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322.
120. Gottesmann MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
121. Grant DS, Williams TL, Zahaczewsky M, and Dicker AP (2003) Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 104:121-129.
122. Grasselli G, Vigano L, Capri G, Locatelli A, Tarenzi E, Spreafico C, Bertuzzi A, Giani A, Materazzo C, Cresta S, et al. (2001) Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. J Clin Oncol 19:2222-2231.
123. Green PS and Leeuwenburgh C (2002) Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta 1588:94-101.
124. Guano F, Pourquier P, Tinelli S, Binaschi M, Bigioni M, Animati F, Manzini S, Zunino F, Kohlhagen G, Pommier Y, and Capranico G (1999) Topoisomerase poisoning activity of novel disaccharide anthracyclines. Mol Pharmacol 56:77-84.
125. Hahn WC (2003) Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 21:2034-2043.
126. Halford S, Yip D, Karapetis CS, Stricland AH, Steger A, Khawaja HT, and Harper PG (2001) A phase II study evaluating the tolerability and efficacy of Caelyx (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma. Ann Oncol 12:1399-1402.
127. Harrington KJ, Lewanski C, Northcote AD, Whittaker J, Peters AM, Vile RG, and Stewart JS (2001) Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer 37:2015-2022.
128. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, Welles L, and Winer E (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:25-36.
129. Hasinoff BB, Abram ME, Barnabé N, Khélifa T, Allan WP, and Yalowich JC (2001) The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol 59:453-461.
130. Hasinoff BB, Creighton AM, Kozlowska H, Thampatty P, Allan WP, and Yalowich JC (1997) Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site. Mol Pharmacol 52:839-845.
131. Hasinoff BB, Schnabl KL, Marusak RA, Patel D, and Huebner E (2003a) Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol 3:89-99.
132. Hasinoff BB, Schroeder PE, and Patel D (2003b) The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol Pharmacol 64:670-678.
133. Hazra TK, Hill JW, Izumi T, and Mitra S (2001) Multiple DNA glycosylases for repair of 8-oxoguanine and their potential in vivo functions. Prog Nucleic Acid Res Mol Biol 68:193-205.
134. 2+ channel modulates apoptosis of cardiac myocytes. FASEB J 16:99-101.
135. Hengge UR, Esser S, Rudel HP, and Goos M (2001) Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. Eur J Cancer 37: 878-883.
136. Heon S, Bernier M, Servant N, Dostanic S, Wang C, Kirby GM, Alpert L, and Chalifour LE (2003) Dexrazoxane does not protect against doxorubicin-induced damage in young rats. Am J Physiol 285:H499-H506.
137. Herbert BS, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, and Corey DR (1999) Inhibition of human telomerase in immortal human cells lead to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 96:14276-14281.
138. Hjalmarson A and Waagstein F (1994) The role of β-blockers in the treatment of cardiomyopathy and ischaemic heart failure. Drugs 47 (Suppl 4):31-39.
139. Hochster H, Liebes L, Wadler S, Oratz R, Wernz JC, Meyers M, Green M, Blum RH, and Speyer JL (1992) Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 84:1725-1730.
140. Hoffmann L, Moller P, Pedersen-Bjergaard J, Waage A, Pedersen M, and Hirsch FR (1995) Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II: a report of two cases and a review of the literature. Ann Oncol 6:781-788.
141. Hopewel JW, Duncan R, Wilding D, and Chakrabarti K (2001) Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent. Hum Exp Toxicol 20:461-470.
142. Husken BC, de Jong J, Beekman B, Onderwater RC, van der Vijgh WJ, and Bast A (1997) Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids. Cancer Chemother Pharmacol 37:55-62.
143. Hussein MA, Wood L, Hsi E, Srkalovic G, Karam M, Elson P, and Bukowski RM (2002) A Phase II trial of pegylated liposomal doxorubicin, vincristine and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 95:2160-2168.
144. Inoue A, Narumi K, Matsubara S, Sugawara S, Saijo Y, Satoh K, and Nukiwa T (2000) Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett 157:105-112.
145. Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, Gahlmann R, Lyons G, Kedes L, and Torti FM (1990) Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 87:4275-4279.
146. Jain KK, Casper ES, Geller NL, Hakes TB, Kaufman RJ, Currie V, Schwartz W, Cassidy C, Petroni GR, and Young CW (1985) A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3:818-826.
147. Jaruga P and Dizdaroglu M (1996) Repair of products of oxidative DNA base damage in human cells. Nucleic Acids Res 24:1389-1394.
148. Jensen LH, Nitiss KC, Rose A, Dong J, Zhou J, Hu T, Osheroff N, Jensen PB, Sehested M, and Nitiss JL (2000) A novel mechanism of cell killing by antitopoisomerase II bisdioxopiperazines. J Biol Chem 275:2137-2146.
149. Jeyaseelan R, Poizat C, Baker RK, Abdishoo S, Isterabadi LB, Lyons GE, and Kedes L (1997a) A novel cardiac-restricted target for doxorubicinCARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes. J Biol Chem 272:22800-22808.
150. Jeyaseelan R, Poizat C, Wu HY, and Kedes L (1997b) Molecular mechanisms of doxorubicin-induced cardiomyopathy: selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. J Biol Chem 272:5828-5832.
151. Ji C, Rouzer CA, Marnett LJ, and Pietenpol JA (1998) Induction of cell cycle arrest by the endogenous product of lipid peroxidation, malondialdehyde. Carcinogenesis 19:1275-1283.
152. Johnston SRD and Gore ME (2001) Caelyx: phase II studies in ovarian cancer. Eur J Cancer 37:S8-S14.
153. Jonsson-Videsater K, Andersson G, Bergh J, and Paul C (2003) Doxorubicin-resistant, MRP1-expressing U-1285 cells are sensitive to idarubicin. Ther Drug Monit 25:331-339.
154. Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, van Oosterom AT, Clemons MJ, Kamby C, Hermans C, et al. (2001) Randomised Phase II trial of pegylated liposomal doxorubicin (Doxil/Caelyx) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37:870-877.
155. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, and Kotamraju S (2002) Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234/235:119-124.
156. Kang JV, Zhou ZX, Wang G-W Buridi A, and Klein JB (2000) Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem 275:13690-13698.
157. Kang PM, Yue P, and Izumo S (2002) New insights into the role of apoptosis in cardiovascular disease. Circ J 66:1-9.
158. Kang W and Weiss M (2003) Modeling the metabolism of idarubicin to idarubicinol in rat heart: effect of rutin and phenobarbital. Drug Metab Dispos 31:462-468.
159. Kato S, Burke PJ, Koch TH, and Bierbaum VM (2001) Formaldehyde in human cancer cells: detection by preconcentration-chemical ionization mass spectrometry. Anal Chem 73:2992-2997.
160. Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q, Cheng K, Chen YN, Campbell A, Sudha T, et al. (2000) Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x (L) in response to DNA damage. J Biol Chem 275:322-327.
161. Kim JH, Lee GE, Kim JC, Lee JH, and Chung IK (2002a) A novel telomere elongation in an adriamycin-resistant stomach cancer cell line with decreased telomerase activity. Mol Cells 13:228-236.
162. Kim M-Y, Gleason-Guzman M, Izbicka E, Nishioka D, and Hurley LH (2003a) The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures. Cancer Res 63:3247-3256.
163. Kim R, Tanabe K, Uchida Y, Emi M, Inoue H, and Toge T (2002b) Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol 50:343-352.
164. Kim Y, Ma AG, Kitta K, Fitch SN, Ikeda T, Ihara Y, Simon AR, Evans T, and Suzuki YJ (2003b) Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol Pharmacol 63:368-377.
165. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, and Papahadjopoulos D (1997) Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36:66-75.
166. Kitta K, Day RM, Kim Y, Torregroza I, Evans T, and Suzuki YJ (2003) Hepatocyte growth factor induces GATA-4 phosphorylation and cell survival in cardiac muscle cells. J Biol Chem 278:4705-4712.
167. Kiyomiya K, Kurebe M, Nakagawa H, and Matsuo S (2002a) The role of the proteasome in apoptosis induced by anthracycline anticancer agents. Int J Oncol 20: 1205-1209.
168. Kiyomiya K, Matsuo S, and Kurebe M (2001a) Differences in intracellular sites of action of Adriamycin in neoplastic and normal differentiated cells. Cancer Chemother Pharmacol 47:51-56.
169. Kiyomiya K, Matsuo S, and Kurebe M (2001b) Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex. Cancer Res 61:2467-2471.
170. Kiyomiya K, Satoh J, Horie H, Kurebe M, Nakagawa H, and Matsuo S (2002b) Correlation between nuclear action of anthracycline anticancer agents and their binding affinity to the proteasome. Int J Oncol 21:1081-1085.
171. Koh E, Ueda Y, Nakamura T, Kobayashi A, Katsuta S, and Takahashi H (2002) Apoptosis in young rats with adriamycin-induced cardiomyopathy-comparison with pirarubicin, a new anthracycline derivative. Pediatr Res 51:256-259.
172. Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, and Kalyanaraman B (2002) Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem 277:17179-17187.
173. Koukourakis MI, Koukouraki S, Fezoulidis I, Kelekis N, Kyrias G, Archimandritis S, and Karkavitsas N (2001) High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br J Cancer 83:1281-1286.
174. Kumar D, Kirshenbaum LA, Li T, Daselisen I, and Singal PK (2001) Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal 3:135-145.
175. Kuratsu JI, Arita N, Kayama T, Kubo N, Mori T, Sawamura Y, and Ushio Y (2000) Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients. J Neurooncol 48:145-149.
176. Kuznetsov DD, Alsikafi NF, O'Connor RC, and Steinberg GD (2001) Intravesical valrubicin in the treatment of carcinoma in situ of the bladder. Expert Opin Pharmacother 2:1009-1013.
177. Kwok JC and Richardson DR (2002) Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity. Mol Pharmacol 62:888-900.
178. Kwok JC and Richardson DR (2003) Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol 63:849-861.
179. Kwok JC and Richardson DR (2004) Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors and lysosomotropic agents. Mol Pharmacol 65:181-195.
180. Ladas EJ, Jacobson JS, Kennedy DD, Teel K, Fleischauer A, and Kelly KM (2004) Antioxidants and cancer therapy: a systematic review. J Clin Oncol 22:517-528.
181. Lage M, Helbach H, Dietel M, and Schadendorf D (2000) Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer 82:488-491.
182. Lampidis TJ, Kolonias D, Podona T, Israel M, Safa AR, Lothstein L, Savaraj N, Tapiero H, and Priebe W (1997) Circumvention of P-gp MDR as a function of anthracycline lipophilicity and charge. Biochemistry 36:2679-2685.
183. Laurent G and Jaffrezou JP (2001) Signaling pathways activated by daunorubicin. Blood 98:913-924.
184. Lee K-H, Rudolph KL, Ju Y-J, Greenberg RA, Cannizzaro L, Chin L, Weiler SR, and DePinho RA (2001) Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc Natl Acad Sci USA 98:3381-3386.
185. Lefrak EA, Pitha J, Rosenheim S, and Gottlieb JA (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302-314.
186. Legha SS, Benjamin RS, Mackay B, Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, et al. (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133-139.
187. Leri A, Franco S, Zacheo A, Barlucchi L, Chimenti S, Limana F, Nadal-Ginard B, Kajstura J, Anversa P, and Blasco MA (2003) Ablation of telomerase and telomere loss leads to cardiac dilatation and heart failure associated with p53 upregulation. EMBO (Eur Mol Biol Organ) J 22:131-139.
188. Lewis AD, Lau DH, Duran GE, Wolf CR, and Sikic BI (1992) Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. Cancer Res 52:4379-4384,
189. Li T, Danelisen I, and Singal PK (2002) Early changes in myocardial antioxidant enzymes in rats treated with adriamycin. Mol Cell Biochem 232:19-26.
190. Li T and Singal PK (2000) Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 102:2105-2110.
191. Licata S, Saponiero A, Mordente A, and Minotti G (2000) Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem Res Toxicol 13:414-420.
192. Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM, Suter TM, Liao R, and Sawyer DB (2004) Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 279:8290-8299.
193. Lipp HP and Bokemeyer C (1999) Anthracyclines and other intercalating agents, in: Anticancer Drug Toxicity: Prevention, Management and Clinical Pharmacokinetics (Lipp HP ed) pp 81-113, Marcel Dekker, Inc., New York.
194. Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, et al. (2002a) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 20:1677-1682.
195. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD, and Colan SD (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738-1743.
196. Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC 2nd, Shaikh SL, Mone SM, Gelber RD, and Colan SD (2002b) Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 20: 4517-4522.
197. Liu L, Hausladen A, Zeng M, Que L, Heitman J, and Stamler JS (2001) A metabolic enzyme for S-nitrosothiol conserved from bacteria to humans. Nature (Lond) 410:490-494.
198. Lopes de Menezes DE, Pilarski LM, Belch AR, and Allen TM (2000) Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim Biophys Acta 1466:205-220.
199. Lothstein L, Israel M, and Sweatman TM (2001) Anthracycline drug targeting: cytoplasmic versus nuclear-a fork in the road. Drug Resist Updat 4:169-177.
200. Lothstein L, Rodrigues PJ, Sweatman TW, and Israel M (1998) Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length. Anticancer Drugs 9:58-66.
201. Lothstein L, Wright HM, Sweatman TW, and Israel M (1992) N-benzyladriamycin-14-valerate and drug resistance: correlation of anthracycline structural modification with intracellular accumulation and distribution in multidrug resistant cells. Oncol Res 4:341-347.
202. Lu K, Savaraj N, Kavanagh J, Feun LG, Burgess M, Bodey GP, and Loo TL (1986) Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). Cancer Chemother Pharmacol 17:143-148.
203. Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, Harley CB, and von Zglinicki T (2001) Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res 61:3053-3061.
204. Lunardi G, Vannozzi MO, Bighin C, Del Mastro L, Stevani I, Schettini G, and Venturini M (2003) Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. Ann Oncol 14:1222-1226.
205. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, and Gabizon A (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89:1037-1047.
206. Manciu L, Chang X, Riordan JR, Buyse F, and Ruysschaert JM (2001) Nucleotide-induced conformational changes in the human multidrug resistance protein MRP1 are related to the capacity of chemotherapeutic drugs to accumulate or not in resistant cells. FEBS Lett 493:31-35.
207. Marchetti A, Pellegrini C, Buttitta F, Falleni M, Romagnoli S, Felicioni L, Barassi F, Salvatore S, Chella A, Angeletti CA, et al. (2002) Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation. Lab Investig 82:729-736.
208. Marchini S, Cozzi P, Beria I, Geroni C, Capolongo L, D'Incalci M, and Broggini M (1998) Sequence-specific, DNA alkylation of novel tallimustine derivatives. Anticancer Drug Des 13:193-205.
209. Marchini S, Damia G, Broggini M, Pennella G, Ripamonti M, Marsiglio A, and Geroni C (2001) 4-Demethoxy-3′-deamino-3′-aziridinyl-4′ -methylsulphonyldaunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms. Cancer Res 61:1991-1995.
210. Marina NM, Cochrane D, Harney E, Zomorodi K, Blaney S, Winick N, Bernstein M, and Link MP (2002) Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study, Clin Cancer Res 8:413-418.
211. Markman M, Homesley H, Norberts DA, Schink J, Abbas F, Miller A, Soper J, Teng N, Hammond N, Muggia F, et al. (1996) Phase I trial of intraperitoneal AD-32 in gynecologic malignancies. Gynecol Oncol 61:90-93.
212. Marnett LJ, Riggins JN, and West JD (2003) Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J Clin Investig 111:583-593.
213. 2 induce caspase-3-independent degradation of Akt/protein kinase B. J Biol Chem 277:42943-42952.
214. Martin FJ (1998) Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin), in Medical Applications of Liposomes (Lasic DD and Papahadjopoulos D eds) pp 635-688, Elsevier Science Inc., New York.
215. Mavroudis D, Kouroussis CH, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Samonis G, and Georgoulias V (2002) Phase I study of paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) administered every 2 weeks in patients with advanced solid tumors. Oncology 62:216-222.
216. Mayer LD, Dougherty G, Harasym TO, and Bally MB (1997) The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther 280:1406-1414.
217. McBride NC, Cavenagh JD, Ward MC, Grant I, Schey S, Gray A, Hughes A, Mills MJ, Cervi P, Newland AC, and Kelsey SM (2001) Liposomal daunorubicin (Daunoxome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkin's lymphoma. Leuk Lymphoma 42:89-98.
218. Meissner K, Sperker B, Karsten C, Zu Schwabedissen HM, Seeland U, Bohm M, Bien S, Dazert P, Kunert-Keil C, Vogelgesang S, et al. (2002) Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J Histochem Cytochem 50:1351-1356.
219. Menna P, Salvatorelli E, Giampietro R, Liberi G, Teodori G, Calafiore AM, and Minotti G (2002) Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines. Chem Res Toxicol 15:1179-1189.
220. Mihm MJ, Yu F, Weinstein DM, Reiser PJ, and Bauer JA (2002) Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase. Br J Pharmacol 135:581-588.
221. Mimnaugh EG, Fairchild CR, Fruehauf JP, and Sinha BK (1991) Biochemical and pharmacological characterization of MCF-7 drug-sensitive and AdrR multidrug-resistant human breast tumor xenografts in athymic nude mice. Biochem Pharmacol 42:391-402.
222. Minotti G (1993) Sources and role of iron in lipid peroxidation. Chem Res Toxicol 6:134-146.
223. Minotti G, Cairo G, and Monti E (1999) Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J 13:199-212.
224. Minotti G, Cavaliere AF, Mordente A, Rossi M, Schiavello R, Zamparelli R, and Possati GF (1995) Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. J Clin Investig 95:1595-1605.
225. 4S]-reactivity of its secondary alcohol metabolite. Chem Res Toxicol 13:1336-1341.
226. Minotti G, Mancuso C, Frustaci A, Mordente A, Santini SA, Calafiore AM, Liberi G, and Gentiloni N (1996) Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. J Clin Investig 98:650-661.
227. Minotti G, Parlani M, Salvatorelli E, Menna P, Cipollone A, Animati F, Maggi CA, and Manzini S (2001a) Impairment of myocardial contractility by anticancer authracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue. Br J Pharmacol 134:1271-1280.
228. Minotti G, Recalcati S, Menna P, Salvatorelli E, Coma G, and Cairo G (2004) Doxorubicin cardiotoxicity and the control of iron metabolism: quinone dependent and independent mechanisms. Methods Enzymol 378:340-361.
229. Minotti G, Recalcati S, Mordente A, Liberi G, Calafiore AM, Mancuso C, Preziosi P, and Cairo G (1998) The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J 12:541-552.
230. Minotti G, Ronchi R, Salvatorelli E, Menna P, and Cairo G (2001b) Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 61:8422-8428.
231. Minotti G, Saponiero A, Licata S, Menna A, Calafiore AM, Teodori G, and Gianni L (2001c) Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res 7:1511-1515.
232. Misset JL, Dieras V, Gruia G, Bourgeois H, Cvitkovic E, Kalla S, Bozec L, Beuzeboc P, Jasmin C, Aussel JP, et al. (1999) Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 10:553-560.
233. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, et al. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377-2380.
234. Miyashita T and Reed JC (1998) Tumor suppressor p53 is a direct transcription activator of the human bax gene. Cell 80:293-299.
235. Moase EH, Qi W, Ishida T, Gabos Z, Longenecker BM, Zimmermann GL, Ding L, Krantz M, and Allen TM (2001) Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim Biophys Acta 1510:43-55.
236. Mohrbacher AF, Gregory SA, Gabriel DA, Rusk JM, and Giles FJ (2002) Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study. Cancer 94:2645-2652.
237. Monneret C (2001) Recent developments in the field of antitumour anthracyclines. Eur J Med Chem 36:483-493.
238. Mordente A, Minotti G, Martorana GE, Silvestrini A, Giardina B, and Meucci E (2003) Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochem Pharmacol 66:989-998.
239. Muggia FM, Blessing JA, Sorosky J, and Reid GC (2002) Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol 9:2360-2364.
240. Myers CE (1998) The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 25 (Suppl 10):10-14.
241. Naasani I, Oh-hashi F, Oh-hara T, Feng WY, Johnston J, Chan K, and Tsuruo T (2003) Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res 63:824-830.
242. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, et al. (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968-975.
243. Nabholtz JM, North S, Smylie M, Mackey J, Au HJ, Au R, Morrish D, Salter E, and Tonkin K (2000) Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer. Semin Oncol 27 (Suppl 3):11-18.
244. Nakajima A, Tauchi T, Sashida G, Sumi M, Abe K, Yamamato K, Ohyashiki JH, and Ohyashiki K (2003) Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia 17:560-567.
245. Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, and Koh E (2000) Fas-Mediated apoptosis in adriamycin-induced cardiomyopathy in rats. Circulation 102:572-578.
246. Narahari J, Ma R, Wang M, and Walden WE (2000) The aconitase function of iron regulatory protein 1. Genetic studies in yeast implicate its role in iron-mediated redox regulation. J Biol Chem 275:16227-16234.
247. Natale RB, Cody RL, Simon MS, and Wheeler RH (1993) An in vivo and in vitro trial of aclarubicin in metastatic breast cancer: a novel approach to the study of analogs. Cancer Chemother Pharmacol 31:485-488.
248. Negoro S, Oh H, Tone E, Kunisada K, Fujio Y, Walsh K, Kishimoto T, and Yamauchi-Takihara K (2001) Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation 103:555-561.
249. Niedernhofer LJ, Daniels JS, Rouzer CA, Greene RE, and Marnett LJ (2003) Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. J Biol Chem 278:31426-31433.
250. Niitsu N, Yamazaki J, Nakayama M, and Umeda M (1998) Pirarubicin-induced myocardial damage in elderly patients with non-Hodgkin's lymphoma. Nippon Ronen Igakkai Zasshi 35:358-362.
251. Nobori K, Ito H, Tamamori-Adachi M, Adachi S, Ono Y, Kawauchi J, Kitajima S, Marumo F, and Isobe M (2002) ATF3 inhibits doxorubicin-induced apoptosis in cardiac myocytes: a novel cardioprotective role of ATF3. J Mol Cell Cardiol 34: 1387-1397.
252. Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, Rios A, Krown SE, DuMond C, and Mamelok RD (1997) Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15:653-659.
253. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, and Henry DH (1998) Pegylated liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16:2445-2451.
254. Nunez M, Saballs P, Valencia ME, Santos J, Ferrer E, Santos I, Berrocal A, Galindo MJ, Podzamczer D, and Gonzalez-Lahoz J (Caelyx/KS Spanish Study Group) (2001) Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy. HIV Clin Trials 2:429-437.
255. O'Byrne KJ, Thomas AL, Sharma RA, DeCatris M, Shields F, Beare S, and Steward WP (2002) A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer 87:15-20.
256. Ogiso Y, Tomida A, Lei S, Oura S, and Tsuruo T (2000) Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 60:2429-2434.
257. Ogiso Y, Tomida A, and Tsuruo T (2002) Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase II-directed drugs. Cancer Res 62:5008-5012.
258. Ogretmen B, Schady D, Usta J, Wood R, Kraveka JM, Luberto C, Birbes H, Hannun YA, and Obeid LM (2001) Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. J Biol Chem 276:24901-24910.
259. Oh H, Wang SC, Prahash A, Sano M, Moravec CS, Taffet GE, Michael LH, Youker KA, Entman ML, and Schneider MD (2003) Telomere attrition and Chk2 activation in human heart failure. Proc Natl Acad Sci USA 100:5378-5383.
260. Olinski R, Jaruga P, Foksinski M, Bialkowski K, and Tujakowski J (1997) Epirubicin-induced oxidative DNA damage and evidence for its repair in lymphocytes of cancer patients who are undergoing chemotherapy. Mol Pharmacol 52:882-885.
261. Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL, and Reeves RH (2003) Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 63:6602-6606.
262. Olson RD, Li X, Palade P, Shadle SE, Mushlin PS, Gambliel HA, Fill M, Boucek RJ Jr, and Cusack BJ (2000) Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Toxicol Appl Pharmacol 169: 168-176.
263. Olson RD and Mushlin PS (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 4:3076-3086.
264. Otteneder M, Scott Daniels J, Voehler M, and Marnett LJ (2003) Development of a method for determination of the malondialdehyde-deoxyguanosine adduct in urine using liquid chromatography-tandem mass spectrometry. Anal Biochem 315:147-151.
265. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hubner N, Chien KR, Birchmeier C, and Garratt AN (2002) Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 99:8880-8885.
266. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L, Deb A, Szabo E, Ungvari Z, Wolin MS, et al. (2003) Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107:896-904.
267. Pagani O, Sessa C, Nole F, Crivellari D, Lombardi D, Thurlimann B, Hess D, Borner M, Bauer J, Martinelli G, et al. (2000) Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Ann Oncol 11:985-991.
268. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, et al. (2002) Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172-1181.
269. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, and Ponzoni M (2003a) Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 63:7400-7409.
270. Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase EH, Allen TM, and Ponzoni M (2003b) Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 63:86-92.
271. Patel VA, Dunn MJ, and Sorokin A (2002) Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 277:38915-38920.
272. Penault-Llorca F, Cayre A, Bouchet Mishellany F, Amat S, Feillel V, Le Bouedec G, Ferriere JP, De Latour M, and Chollet P (2003) Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 22:1319-1325.
273. Perego P, Corna E, De Cesare M, Gatti L, Polizzi D, Pratesi G, Supino R, and Zunino F (2001) Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem 8:31-37.
274. Perez EA and Rodeheffer R (2004) Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22:322-329.
275. Perez-Soler R, Sugarman S, Zou Y, and Priebe W (1995) Anthracycline antibiotics, new analogues, methods of delivery and mechanisms of action. Am Chem Soc Symp Ser 574:300-319.
276. Perotti A, Cresta S, Grasselli G, Capri G, Minotti G, and Gianni L (2003) Cardiotoxic effects of anthracycline-taxane combinations (2003) Expert Opin Drug Saf 2:59-71.
277. Pinkel D, Camitta B, Kun L, Howarth C, and Tang T (1982) Doxorubicin cardiomyopathy in children with left-sided Wilms tumor. Med Pediatr Oncol 10:483-488.
278. Plastaras JP, Dedon PC, and Marnett LJ (2002) Effects of DNA structure on oxopropenylation by the endogenous mutagens malondialdehyde and base propenal. Biochemistry 41:5033-5042.
279. Platel D, Bonoron-Adele S, and Robert J (2001) Role of daunorubicinol in daunorubicin-induced cardiotoxicity as evaluated with the model of isolated perfused rat heart. Pharmacol Toxicol 88:250-254.
280. Poulaki V, Mitsiades CS, Joussen AM, Lappas A, Kirchhof B, and Mitsiades N (2002) Constitutive nuclear factor-κB activity is crucial for human retinoblastoma cell viability. Am J Pathol 161:2229-2240.
281. Pratesi G, De Cesare M, Caserini C, Perego P, Dal Bo L, Polizzi D, Supino R, Bigioni M, Manzini S, Iafrate E, et al. (1998) Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts. Clin Cancer Res 4:2833-2839.
282. Reszka KJ, McCormick ML, and Britigan BE (2001) Peroxidase- and nitrite-dependent metabolism of the anthracycline anticancer agents daunorubicin and doxorubicin. Biochemistry 40:15349-15361.
283. Ripamonti M, Capolongo L, Melegaro G, Gornati C, Bargiotti A, Caruso M, Grandi M, and Suarato A (1996) Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives (1996) Investig New Drugs 14:139-146.
284. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL 3rd, Pusztai L, and Hortobagyi GN (2003) Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21:3249-3254.
285. Rivera E, Valero V, Esteva FJ, Syrewicz L, Cristofanilli M, Rahman Z, Booser DJ, and Hortobagyi GN (2002) Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother Pharmacol 49:299-302.
286. Roaten JB, Kazanietz MG, Caloca MJ, Bertics PJ, Lothstein L, Parrill AL, Israel M, and Sweatinan TW (2002) Interaction of the novel anthracycline antitumor agent N-benzyladriamycin-14-valerate with the C1-regulatory domain of protein kinase C: structural requirements, isoform specificity and correlation with drug cytotoxicity. Mol Cancer Ther 1:483-492.
287. Robert J (1993) Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs 45 (Suppl 2):20-30.
288. Robert J and Gianni L (1993) Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 17:219-252.
289. Rocha S, Soengas MS, Lowe SW, Rocha S, Soengas MS, Lowe SW, Glanzmann C, Fabbro D, Winterhalter K, Bodis S, and Pruschy M (2000) Protein kinase C inhibitor and irradiation-induced apoptosis: relevance of the cytochrome c-mediated caspase-9 death pathway. Cell Growth Differ 11:491-499.
290. Rudra PK and Krokan HE (2001) Cell-specific enhancement of doxorubicin toxicity in human tumour cells by docosahexaenoic acid. Anticancer Res 21:29-38.
291. Ruiz-Ruiz C, Robledo G, Cano E, Redondo JM, and Lopez-Rivas A (2003) Characterization of p53-mediated up-regulation of CD95 gene expression upon genotoxic treatment in human breast tumor cells. J Biol Chem 278:31667-31675.
292. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, and Dombernowsky P (1998) Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 16:3502-3508.
293. Sacco G, Giampietro R, Salvatorelli E, Menna P, Bertani N, Graiani G,
294. Sadava D, Coleman A, and Kane SE (2002) Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J Liposome Res 12:301-309.
295. 2. Ann Oncol 11:1029-1033.
296. Saraste A, Pulkki K, Kallajoki M, Heikkila P, Laine P, Mattila S, Nieminen MS, Parvinen M, and Voipio-Pulkki LM (1999) Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur J Clin Investig 29:380-386.
297. Sato Y, Eddy L, and Hochstein P (1991) Comparative cardiotoxicity of doxorubicin and a morpholino anthracycline derivative (KRN8602). Biochem Pharmacol 42: 2283-2287.
298. Sawyer DB, Fukazawa R, Arstall MA, and Kelly RA (1999) Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 84:257-265.
299. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, and Suter TM (2002) Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1β and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105:1551-1554.
300. Schneider JW, Chang AY, and Garratt A (2002) Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study. Semin Oncol 29 (Suppl 11):22-28.
301. Schrijvers D, Bos AM, Dyck J, de Vries EG, Wanders J, Roelvink M, Fumoleau P, Bortini S, and Vermorken JB (2002) Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group. Ann Oncol 13:385-391.
302. Schroder CP, Wisman GB, de Jong S, van der Graaf WT, Ruiters MH, Mulder NH, de Leij LF, van der Zee AG, and de Vries EG (2001) Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer 84:1348-1353.
303. Schroeder PE, Davidson JN, and Hasinoff BB (2002) Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187). Drug Metab Dispos 30:1431-1435.
304. Schroeder PE and Hasinoff BB (2002) The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925. Cancer Chemother Pharmacol 50:509-513.
305. Schuchter LM, Hensley ML, Meropol NJ, and Winer EP (2002) American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20:2895-2903.
306. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, and Keefe D (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221.
307. Sessa C, Perotti A, Salvatorelli E, Minotti G, Vigano L, Lladò A, Capri G, Locatelli A, Colombini S, Peccatori F, et al. (2004) Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. Eur J Cancer 40:560-570.
308. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, and Kerr DJ (2002) Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 20:1668-1676.
309. Shadle SE, Bammel BP, Cusack BJ, Knighton RA, Olson SJ, Mushlin PS, and Olson RD (2000) Daunorubicin cardiotoxicity: evidence for the importance of the quinone moiety in a free-radical-independent mechanism. Biochem Pharmacol 60:1435-1444.
310. Singal PK and Iliskovic N (1998) Adriamycin cardiomyopathy. N Engl J Med 339: 900-905.
311. Singal PK, Iliskovic N, Li T, and Kumar D (1997) Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 11:931-936.
312. Singal PK, Li T, Kumar D, Danelisen I, and Iliskovic N (2000) Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 207:77-85.
313. Singh B and Lucci A (2002) Role of cyclooxygenase-2 in breast cancer. J Surg Res 108:173-179.
314. Siveski-Iliskovic N, Hill M, Chow DA, and Singal PK (1995) Probucol protects against adriamycin cardiomyopathy without interfering with its anti-tumor properties. Circulation 91:10-15.
315. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792.
316. Sokolove PM (1994) Interactions of adriamycin aglycones with mitochondria may mediate adriamycin cardiotoxicity. Int J Biochem 26:1341-1350.
317. Sparano JA, Malik U, Rajdev L, Sarta C, Hopkins U, and Wolff AC (2001) Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol 19:3117-3125.
318. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz J, Rey M, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M, et al. (1992) ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127.
319. Spycher SE, Tabataba-Vakili S, O'Donnell VB, Palomba L, and Azzi A (1997) Aldose reductase inductions novel response to oxidative stress of smooth muscle cells. FASEB J 11:181-188.
320. Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, et al. (2003) A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 9:124-133.
321. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, and Murphy L (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA (J Am Med Assoc) 266:1672-1677.
322. Stewart DJ, Grewaal D, Green RM, Mikhael N, Goel R, Montpetit VA, and Redmond MD (1993) Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res 13:1945-1952.
323. Storm G, Steerenberg PA, Emmen F, Waalkes MvB, and Crommelin DJA (1988) Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. Biochim Biophys Acta 965:136-145.
324. Sun X, Zhou Z, and Kang YJ (2001) Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart. Cancer Res 61:3382-3387.
325. Swain SM (1998) Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol 25 (4 Suppl 10):43-47.
326. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, et al. (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332.
327. Swift LP, Cutts SM, Rephaeli AM, Nudelman A, and Phillips DR (2002) Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine. Mol Cancer Ther 2:189-198.
328. Synold TW and Doroshow JH (1996) Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion. J Infus Chemother 6:69-73.
329. Taatjes DJ, Fenick DJ, and Koch TH (1998) Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells. J Med Chem 41:1306-1314.
330. Taatjes DJ, Fenick DJ, and Koch TH (1999) Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines. Chem Res Toxicol 12:588-596.
331. Taatjes DJ, Gaudiano G, Resing K, and Koch TH (1997) Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J Med Chem 40:1276-1286.
332. Taatjes DJ and Koch TH (2001) Nuclear targeting and retention of anthracycline antitumor drugs in sensitive and resistant tumor cells. Curr Med Chem 8:15-29.
333. Takemoto Y, Sampi K, Kuraishi Y, Okabe K, Tamura K, Mizoguchi H, Saito H, Masaoka T, and Ogawa M (1999) A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group. Int J Hematol 70:20-25.
334. Tan B, Piwnica-Worms D, and Ratner L (2000) Multidrug resistance transporters and modulation. Curr Opin Oncol 12:450-458.
335. Temperini C, Messori L, Orioli P, Di Bugno C, Animati F, and Ughetto G (2003) The crystal structure of the complex between a disaccharide anthracycline and the DNA hexamer d(CGATCG) reveals two different binding sites involving two DNA duplexes. Nucleic Acids Res 31:1464-1469.
336. Tetef ML, Synold TW, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Yen Y, et al. (2001) Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. Clin Cancer Res 7:1569-1576.
337. Thomas AL, O'Byrne K, Furber L, Jeffery K, and Steward WP (2001) A phase II study of Caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer. Cancer Chemother Pharmacol 48:266-268.
338. Thomas X, Le QH, and Fiere D (2002) Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukaemia. Ann Hematol 81:504-507.
339. Toffoli G, Simone F, Gigante M, and Boiocchi M (1994) Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant Lovo cell lines. Biochem Pharmacol 4:1871-1881.
340. Toffoli G, Sorio R, Aita P, Crivellari D, Corona P, Bearz A, Robieux I, Colussi AM, Stocco F, and Baiocchi M (2000) Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. Clin Cancer Res 6:2279-2287.
341. Toffoli G, Sorio R, Aita P, Crivellari D, Corona G, Rimondi G, Bearz A, Stocco F, Robieux I, and Boiocchi M (1997) Pharmacology of chronic oral daily administration of idarubicin. Haematologica 82:1-3.
342. Tokarska-Schlattner M, Wallimann T, and Schlattner U (2002) Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. Mol Pharmacol 61:516-523.
343. Torti SV, Akimoto H, Lin K, Billingham ME, and Torti FM (1998) Selective inhibition of muscle gene expression by oxidative stress in cardiac cells. J Mol Cell Cardiol 30:1173-1180.
344. Tournier C, Hess P, Yang DD Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, and Davis RJ (2000) Requirement of JNK for stress induced activation of the cytochrome c-mediated death pathway. Science (Wash DC) 288:870-874.
345. Trouet A, Passioukov A, Van derpoorten K, Fernandez AM, Abarca-Quinones J, Baurain R, Lobl TJ, Oliyai C, Shochat D, and Dubois V (2001) Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies. Cancer Res 61:2843-2846.
346. Valero V and Hortobagyi GN (2003) Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol 21:959-962.
347. van Acker FA, Hulshof JW, Haenen GR, Menge WM, van der Vijgh WJ, and Bast A (2001) New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity. Free Radic Biol Med 31:31-37.
348. van Acker SA, Boven E, Kuiper K, van den Berg DJ, Grimbergen JA, Kramer K, Bast A, and van der Vijgh WJ (1997) Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res 3:1747-1754.
349. van der Heijden AG and Witjes JA (2003) Future strategies in the diagnosis, staging and treatment of bladder cancer. Curr Opin Urol 13:389-395.
350. Vasquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA Jr, and Kalyanaraman B (1997) Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 36:11293-11297.
351. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, and Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717.
352. von Zglinicki T, Pilger R, and Sitte N (2000) Accumulation of single-strand breaks is the major cause of telomere shortening in human fibroblasts. Free Radic Biol Med 28:64-74.
353. Wang L, Ma W, Markovich R, Chen JW, and Wang PH (1998a) Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res 83:516-522.
354. Wang L, Ma W, Markovich R, Lee WL, and Wang PH (1998b) Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells. Endocrinology 139:1354-1360.
355. Wang S, Kotamraju S, Konorev E, Kalivendi S, Joseph J, and Kalyanaraman B (2002) Activation of nuclear factor-κB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem J 367:729-740.
356. Wani MK, Koseki Y, Yarber RH, Sweatman TW, Ahmed A, Samant S, Hengesteg A, Israel M, and Robbins KT (2000) Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck. Laryngoscope 110: 2026-2032.
357. Weinstein DM, Mihm MJ, and Bauer JA (2000) Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J Pharmacol Exp Ther 294:396-401.
358. Weiss RB (1992) The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19:670-686.
359. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM, Shirani J, Armstrong RC, and Kitsis RN (2003) A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Investig 111:1497-1504.
360. Wojnar J, Mandecki M, Wnuk-Wojnar AM, and Holowiecki J (1989) Clinical studies on aclacinomycin A cardiotoxicity in adult patients with acute non lymphoblastic leukaemia. Folia Haematol (Leipz) 116:297-303.
361. Wong BK, DeFeo-Jones D, Jones RE, Garsky VM, Feng DM, Oliff A, Chiba M, Ellis JD, and Lin JH (2001) PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites. Drug Metab Dispos 29:313-318.
362. Working PK, Newman MS, Huang SK, Mayhew E, Vaage J, and Lasic DD (1994) Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth liposomes (Doxil). J Liposome Res 4:667-687.
363. Wu W, Lee WL, Wu YY, Chen D, Liu TJ, Jang A, Sharma PM, and Wang PH (2000) Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells. J Biol Chem 275:40113-40119.
364. Yamaoka M, Yamaguchi S, Suzuki T, Okuyama M, Nitobe J, Nakamura N, Mitsui Y, and Tomoike H (2000) Apoptosis in rat cardiac myocytes induced by Fas ligand: priming for Fas-mediated apoptosis with doxorubicin. J Mol Cell Cardiol 32:881-889.
365. Yen HC, Oberley TD, Vichitbandha S, Ho YS, and St Clair DK (1996) The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Investig 98:1253-1260.
366. Yoon KA, Ku JL, Yang JO, and Park JG (2003) Telomerase activity, expression of Bcl-2 and cell cycle regulation in doxorubicin resistant gastric carcinoma cell lines. Int J Mol Med 11:343-348.
367. Zambetti M, Moliterni A, Materazzo C, Stefanelli M, Cipriani S, Valagussa P, Bonadonna G, and Gianni L (2001) Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 19:37-43.
368. Zeman SM, Phillips DR, and Crothers DM (1998) Characterization of covalent adriamycin-DNA adducts. Proc Natl Acad Sci USA 95:11561-11565.
369. Zhang J, Clark JR Jr, Herman EH, and Ferrans VJ (1996) Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine and inhibition by ICRF-187. J Mol Cell Cardiol 28:1931-1943.
370. Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D, and Deisseroth AB (1995) High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res 1:1051-1057.
371. Zhou S, Heller LJ, and Wallace KB (2001a) Interference with calcium-dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats. Toxicol Appl Pharmacol 175:60-67.
372. Zhou S, Starkov A, Froberg MK, Leino RL, and Wallace KB (2001b) Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 61:771-777.
373. Zucchi R and Danesi R (2003) Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem 3:151-171.
374. 2+ handling and contractile function in rat heart. Br J Pharmacol 131:342-348.
375. Zunino F, Pratesi G, and Perego P (2001) Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs. Biochem Pharmacol 61:933-938.